Accurate measurement of allele frequencies between popu-
Introduction
The International HapMap Project (1) has opened the door for a new generation of diagnostic tools aimed at identifying and characterizing human diversity. In particular, it has provided a large resource of single nucleotide polymorphisms (SNPs) that provide much of the variation between different individuals and different ethnic groups. Although most of the SNPs associated with human disease have been described as diallelic, in the last few years, an increasing number of these have been recognized to be triallelic and possibly even tetraallelic. Most of the multiplex techniques that are being increasingly used for genotyping are based on discerning one allele from the other (i.e., start with the assumption that the allele is diallelic; refs. 2, 3). We wished to consider whether starting with such an assumption could impede the discovery of novel triallelic SNPs, and whether alleles may have been mistyped in the past. This would have implications for the accurate estimation of population data.
The group of cancer-prone inflammatory bowel diseases (IBD) includes ulcerative colitis and Crohn's disease. We used the National Center for Biotechnology Information SNP database to identify variants of genes that are described in the literature as associated with IBD susceptibility: MDR1 (4), DLG5 (5), OCTN1/2 (6), NFkB1 (7), TNF and TNFRSF1B (8) , MIF (9), IL4 (10), and IL11 (11) . Eleven triallelic SNPs have been reported in eight of the identified genes. Interestingly, six of the triallelic SNPs in four of the IBDassociated genes (MDR1, MIF, NFkB1, and TNFRSF1B) have been previously described as diallelic ( Table 1) .
The human MDR1 gene, located on chromosome 7, encodes an ATP-dependent efflux transporter pump (P-glycoprotein) that is highly expressed in various tissues, including the epithelial surfaces of the intestine. The level of expression of P-glycoprotein is critical in determining the pharmacokinetics of a wide-ranging number of substrates, including anticancer drugs (12) (13) (14) (15) . There is considerable interindividual variability in P-glycoprotein expression that has implications not only for the development of resistance to various pharmaceutical agents but also for disease susceptibility (16) . Several SNPs in the MDR1 gene have been associated with susceptibility to the development of various types of cancer (16) , HIV susceptibility (17) , hypercholesteremia (18) , and Parkinson's disease (19) . They have also, arguably, been associated with IBD (4, (20) (21) (22) (23) (24) .
The MDR1 gene is 209 kb in length and composed of 28 exons, and at least 314 SNPs have been described (25) (26) (27) (28) . Thus far, three variants within the gene (G2677T/A in exon 21, C3435T in exon 26, and T129C in exon 1B) have been shown to correlate with a lower P-glycoprotein expression in normal tissues (26, (29) (30) (31) . G2677T and C3435T SNPs are in linkage disequilibrium (multiallelic D ¶ = 0.85; refs. 22, 32, 33) . Considering the triallelic SNP in exon 21, the reference G2677 is Ala 893 , with the T variant being Ser 893 , and the less frequent A variant coding for Thr 893 . Various research groups studying IBD have studied SNPs within MDR1 to determine whether they might be associated with susceptibility to the development of disease. To date, results for the G2677T/A polymorphisms have been controversial (4, 20, 21, 23, 24) ; however, a recent meta-analysis reported evidence for association of the 3435T allele with ulcerative colitis [odds ratio (OR), 1.12; 95% confidence interval, 1.02-1.23] but not Crohn's disease (22) .
We have genotyped DNA samples from a small set of control and Crohn's disease patient samples using a variety of genotyping methods to consider the question as to whether genotyping errors associated with different methods could explain why different studies have not been able to consistently find association to MDR1 SNPs.
Materials and Methods
Study Population. Seventy-three human subjects were recruited either from the Auckland District Health Board gastroenterology clinics or healthy volunteers to provide approximately equal numbers of male and female subjects and controls or IBD patients. Blood samples were collected into heparinized tubes, and DNA was isolated using the Puregene DNA Purification kit (Gentra Systems) according to the manufacturer's protocol. The amount of DNA extracted was quantified by absorbance spectroscopy (260 and 280 nm) and diluted to 10 ng/AL for working solutions. The isolated DNA was stored at À20jC, and the working solutions were stored at 4jC. The study was conducted under ethical protocol MEC/ 04/12/011, authorized through the New Zealand Multi-Region Human Ethics Committee.
Genotyping Methods. The PCR, RFLP, and Taqman SNP Genotyping Assay assays were designed to detect a diallelic rather than a triallelic SNP. The allelic discrimination PCR and Taqman SNP Genotyping Assay assays tested for the presence of G and T alleles, whereas the RFLP detected G allele dosage. All primers used for the different assays (except for the primers obtained for Taqman SNP Genotyping Assay) were obtained from Invitrogen. The techniques were done as follows.
PCR for DNA Sequencing or RFLP. Details of the primers used for amplification of exon 21 are provided in Table 2 . The sequence of the primers was designed using OligoPerfect Designer free software 5 and checked for specificity using the National Center for Biotechnology Information BLAST server. 6 The PCR reactions were done in a 25-AL reaction volume containing 20 ng genomic DNA, 100 pmol of each primer, 0.2 mmol/L of each deoxynucleotide triphosphate, 1Â PCR buffer, 1.5 mmol/L MgCl 2 , and 1 unit Taq polymerase (Qiagen). The PCR program for exon 21 consisted of 30 cycles at 94jC for 30 s, 58jC for 30 s, and 72jC for 30 s and a final elongation step at 72jC for 10 min. The PCR products were checked on a 1.5% agarose gel and photographed before being subjected to a RFLP analysis or DNA sequencing.
RFLP Analysis. To determine the respective genotype (G or T), RFLP analysis with the restriction endonuclease BseYI was conducted after PCR-based amplification (primer listed in Table 2 ). PCR product (10 AL) was combined with 4 units enzyme, 2 AL of 10Â Restriction Enzyme Digestion Buffer 3, and 0.5 AL of bovine serum albumin (all reagents from New England Biolab) in a total volume of 20 AL. Samples were digested for 4 h at 37jC. As the enzyme BseYI remains bound to DNA after digestion and alters migration rate of DNA during electrophoresis, 1 AL of 10% SDS was added after 4 h to disrupt binding. The digestion products were separated on a 2% agarose gel and stained with ethidium bromide.
DNA Sequencing. Amplicons from exon 21 were cleaned according to the manufacturer's instructions using the ChargeSwitch PCR Clean-Up kit (Invitrogen). Automated DNA sequencing was done on an ABI 3130XL Genetic Analyzer sequencer by using BigDye Terminator version 2 reactions (Perkin-Elmer/Applied Biosystems) using the 2677 forward primer.
Conventional Allelic Discrimination PCR. To achieve allelic discrimination between wild-type and mutant allele, two physically separate PCR reactions containing the 2677 forward primer and the corresponding wild-type (2677W) or mutant-specific primer (2677M) were done ( Table 2 ). All reactions were carried out in total volume of 25 AL containing 20 ng genomic DNA, 100 pmol of each primer, 0.2 mmol/L of each deoxynucleotide triphosphate, 1Â PCR buffer, 1.5 mmol/L MgCl 2 , and 1 unit Taq polymerase (Qiagen). The PCR program for allelic discrimination consisted of 30 cycles at 94jC for 30 s, 60jC for 30 s, and 72jC for 30 s and a final elongation step at 72jC for 10 min. The PCR products were electrophoresed on a 1.5% agarose gel, and the genotype assignment was selected on the basis of the following criteria: no visible band represents the absence of the analyzed allele, whereas a band indicates the presence of the analyzed allele.
Applied Biosystems Taqman SNP Genotyping Assay. The SNP at position 2677 of MDR1 was genotyped using the Taqman MGB diallelic discrimination system (34) . Probes and oligonucleotides were obtained from Applied Biosystems using the Assay-by-Design product (listed in Table 2 ). The reactions were prepared by using 2Â Taqman Universal Master Mix, 40Â SNP Genotyping Assay Mix, DNase-free water, and 10 ng genomic DNA in a final volume of 5 AL per reaction. The PCR amplification was done using the ABI Prism 7900 HT sequence-detector machine under the following conditions: 10 min at 95jC enzyme activation followed by 40 cycles at 92jC for 15 s and 60jC for 1 min (annealing/extension). The allelic discrimination results were determined after the amplification by performing an end-point read.
Roche LightCycler Melting Curve Analysis. The LightCycler combines rapid thermal cycling for PCR with real-time fluorescence monitoring (35, 36) . After amplification, the fluorescence signal allows genotyping by analysis of the allelespecific melting behavior of the hybridization probe. The reaction mixture (20 AL) contained 1 unit Taq polymerase, 2 AL of 10Â Taq buffer (GeneCraft), 2.5 mmol/L MgCl 2 , 0.1 mmol/L deoxynucleotide triphosphates (GeneCraft), 
30 mg/L bovine serum albumin (New England Biolab), 50 ml/L dimethyl sulfoxide (Merck), 0.25 mol/L forward primer, 0.1 mol/L reverse primer, 0.15 mol/L of the anchor, 0.05 mol/L of the locked nucleic acid -modified sensor, 1 AL DNA (40-60 ng/L), and water (PCR grade) up to 20 AL. The following program was done: an initial denaturation at 94jC for 2 min at 20jC/s, followed by a 50-cycle program consisting of heating to 94jC at 20jC/s with no hold, cooling to 58jC at 20jC/s with a 10-s hold, and heating to 72jC at 2jC/s with a 15-s hold. The melting curve was determined by 20 s denaturation at 94jC cooling to 32jC at 20jC/s with a 20 s hold by continuous temperature increase from 32jC to 70jC in increments of 0.1jC/s. Fluorescence was recorded continuously while heating.
Sequenom MassARRAY Genotyping System. Genotyping was carried out with a MassARRAY technique (Sequenom; refs. 37, 38) using a chip-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometer (39) . Multiplex SNP assays were designed using SpectroDesigner software (Sequenom); 384-well plates containing 2.5 ng DNA in each well were amplified by PCR following the specifications of Sequenom. After PCR, shrimp alkaline phosphatase (Sequenom) was added to samples to prevent future incorporation of unused deoxynucleotide triphosphates that could interfere with the primer extension assay. Allele discrimination reactions were conducted by adding the extension primer(s), DNA polymerase, and a cocktail mixture of deoxynucleotide triphosphates and dideoxynucleotide triphosphates to each well. MassExtend clean resin (Sequenom) was added to the mixture to remove extraneous salts that could interfere with matrix-assisted laser desorption/ionization time-of-flight analysis. Genotypes were determined by spotting an aliquot of each sample onto a 384 SpectroChip (Sequenom), which was subsequently read by the matrixassisted laser desorption/ionization time-of-flight mass spectrometer. Assay conditions are available upon request and primer sequences are shown in Table 2 .
Estimating the Incidence of Triallelic SNPs in Human Populations. The Seattle SNP database (SeattleSNPs, National Heart, Lung, and Blood Institute Program for Genomic Applications, SeattleSNPs, Seattle, WA) 7 was used to estimate the proportion of SNPs that are triallelic. This database contains polymorphisms identified from DNA sequencing 5.9 Mb from 280 genes in a panel of unrelated subjects. The 280 genes were selected because they are thought to influence inflammatory response in humans. Each gene was genotyped in one panel of subjects. The panel of subjects was either a set of 20 individuals of African-American descent and 19 individuals of European descent, or a set of 20 Yoruba from Ibadan, Nigeria from the YRI HapMap panel and 20 Caucasians from Utah from the CEU HapMap panel (1) . For simplicity, we refer to European and African samples without distinguishing whether the panel with the African-American samples was used, or the panel with the African samples was used.
Results
Allele Frequencies for MDR1 G2677/T/A as Estimated using Six Different Methodologies. The allele frequencies, as estimated by different methods, are shown in Table 3 . The true genotype of each sample was defined as the result of matching genotypes of at least four methods. In the case of only three methods with matching results (six samples), Sequenom MassARRAY Genotyping system had to be one of them (note that in all six cases, DNA sequencing agreed with the Sequenom results). In this population, estimates of the proportion of the G allele ranged from 0.543 (judged by PCR) to 0.589 (LightCycler). Conversely, the T allele appeared lowest when estimated by LightCycler (0.377) and highest using the PCR-based allelic discrimination method (0.457). As most of the known SNPs are diallelic, we wanted to determine what effect the presence of a third allele would have when it is detected in a two-dimensional assay. Thus, the A/G genotype appears as a G/G genotype and an A/T as a T/T genotype in the Taqman assay. None of the PCR methods, RFLP, or Taqman SNP Genotyping Assay provided evidence for the presence of the A allele. However, although our LightCycler method was not designed using knowledge of the third allele, this allele became obvious from the spectra generated (Fig. 1) .
Genotype Errors as Estimated Using Six Different Methodologies. The genotype error analysis is shown in Table 4 . Even when the genotype was called incorrectly, one of the two alleles was usually correct. The only exceptions in our data set were for two T/T genotypes that the LightCycler incorrectly called as G/G and the one T/T that RFLP incorrectly called as G/G.
Most of the errors (6 of 8 RFLP errors, 6 of 7 Taqman SNP Genotyping Assay errors, and 6 of 10 PCR errors) were due to the inability to detect the A allele in the six samples that carried the A allele. RFLP incorrectly called two T/T genotypes (as G/T and G/G), and PCR incorrectly called three G/G genotypes as G/T and one G/T genotype as T/T. The seven LightCycler errors did not have obvious pattern at the genotypic level or the allelic level. This method called six T alleles incorrectly as G alleles and called two G alleles and one A allele incorrectly as T alleles. Even if the six samples with an A allele are ignored, allelic discrimination PCR still showed four errors (error rate = 0.063), and RFLP had two errors in 63 non-missing genotypes. Neither DNA sequencing nor Sequenom MassARRAY Genotyping system generated any errors (Table 4) .
To exclude the possibility that the A allele itself would not be detectable with methods where the knowledge of the third allele is necessary for the assay design, we specifically redesigned two of the assays with respect to the A allele (A/T Taqman assay and allelic discrimination PCR). Neither the Taqman assay nor allelic discrimination PCR failed to detect this allele (data not shown). However, the twodimensional nature of the assay design restricts the Taqman assay to be able to detect only two alleles (A/T in our case) and results in missing another allele (here the G allele). Accordingly, all samples with a G/G genotype failed to amplify, and most of the G/T samples were detected as T/T or failed to amplify. On the other hand, all A/T and T/T genotypes were called correctly. However, in the case of an A/G genotype, the Taqman assay either calls it as an A/A or A/T genotype. No method called a G or T allele as an A allele. The six samples that contained an A allele were genotyped correctly by the DNA sequencing and Sequenom MassARRAY Genotyping system methods. The LightCycler correctly genotyped five of the six samples containing the A allele. However, the number of A alleles in our sample was too small to determine the accuracy of these methods when assaying samples carrying the A genotype.
Missing Genotype Analysis. It seemed that particular genotypes failed with certain methods (Table 5) . Homozygotes (G/G or T/T) seemed to be preferentially missing when using allelic discrimination PCR and Sequenom, whereas heterozygotes (G/T) seemed to be preferentially missing when using DNA Sequencing. The LightCycler and RFLP methods had no missing genotypes.
Estimation of Population Frequencies of Triallelic SNPs.
The Seattle SNP database contained 29,827 diallelic SNPs, 67 triallelic SNPs, and 2,070 insertion/deletion polymorphisms. Therefore, 0.224% of the SNPs in the Seattle SNPs database are triallelic. Of the 67 triallelic SNPs, 12 were triallelic in the European samples, and 53 were triallelic in the African samples. Ten of the SNPs were diallelic in the European samples and in the African samples but were triallelic in the combined samples because the European and African samples had different minor alleles. In the African samples, 19 triallelic SNPs had all three allele frequencies >0.05, and in the European samples, five triallelic SNPs had all three allele frequencies >0.05.
Discussion
It is recognized that some techniques (DNA sequencing and Sequenom MassARRAY Genotyping system analysis) can detect a third allele without knowing of its existence. Our data set suggested this was also true, at least for this allele at this locus, for the LightCycler method. However, most of the multiplex techniques that are being increasingly used for genotyping start with the assumption that the SNP is diallelic (Taqman SNP Genotyping Assay and allelic discrimination PCR) and would need the knowledge of a third allele being present for the assay design, although in some cases, a third allele can be detected by examination of the raw data before analysis (40) . This is also true for RFLP, which is still commonly used for genotyping. Thus, our assay designs for genotyping analysis were based on the assumption that there are only two alleles (G and T), ignoring the presence of the rare A allele. As anticipated, several of the methods failed to provide signals that would have led us to suspect a third allele. Unexpectedly, however, it was not only the A allele that provided difficulties in genotyping with some of the tested methodologies.
Other than hypothesized, it was not apparent that any of the different detection techniques favored one allele over the other. Among all methods tested, the LightCycler and RFLP methods were the only methods that showed no unclear or failed results. Five of seven RFLP genotype errors, five of the six Taqman SNP Genotyping Assay errors, and five of the eight allelic discrimination PCR errors were due to the inability to detect the A allele, as would be expected for these methods. To analyze this further, we designed two sets of assays (Taqman and allelic discrimination PCR) to detect the A allele and have rerun these new assays through our sample set. Both Taqman assay and allelic discrimination PCR provide accurate measurement for the rare A allele.
For family-based studies, genotype error can be a serious problem because it can increase the false positive proportion (41) . For case control studies, genotype error generally will cause a loss in power to detect marker-disease associations but not an increase in the false-positive proportion. The number of genotypes is <73 for some platforms due to failed or unclear assays (see Table 4 ).
The consequences of not detecting a null (i.e., unknown) allele of a triallelic SNP are serious when the null allele affects risk of disease. This can be shown by calculating the population OR for each of the detected alleles in cases and controls for a population that is in Hardy-Weinberg equilibrium. We assume that there are three alleles (a, b, and c) with frequencies p a , p b , and p c , and that allele c is a null allele such that null allele homozygotes have missing genotypes and null allele heterozygotes are miscalled as homozygote genotypes for the non-null allele. Denote the population disease prevalence by / and the genotypic relative risk for c allele heterozygotes as r. Then the apparent population allelic OR for the a allele is:
For example, when the disease prevalence is <0.1, and the risk allele of a triallelic SNP has an allelic OR of 3.0, if the risk allele is not detected, the allelic OR for each of the detected alleles will be <1.25. In the worst case, when the disease model is recessive, or when the detected alleles have equal population frequency, the allelic OR for each of the detected alleles will appear as 1.0, and there will be no power to detect the true disease association.
When the null allele has low frequency, and there is a sufficiently small difference in the frequencies of the detected alleles, the presence of a null allele is unlikely to cause high levels of missing data or departures from Hardy-Weinberg equilibrium. In cases where a null allele does contribute to an unacceptably high level of missing data or departure from Hardy-Weinberg equilibrium, this evidence of error in the genotyping assay will often result in the SNP being dropped from the analysis.
If an assay (like the Taqman SNP Genotyping Assay) is not designed to detect an allele of a triallelic SNP, there will be little or no power to detect an association of the undetected allele with a disease. Even if all three alleles of a triallelic SNP are detected, high error rates, such as those observed with the LightCycler, can cause substantial loss in power (42) .
It was apparent that particular genotypes failed with certain methods. Homozygotes (G/G and T/T) seemed to be preferentially missing when using allelic discrimination PCR and Sequenom MassARRAY Genotyping system, whereas heterozygotes (G/T) seemed to be preferentially missing when using DNA sequencing. The genotyping failures of all methods are not based on the DNA quality, as no sample failed with more then one method. Another explanation for this failure rate could be the occurrence of allelic dropouts, whereby an unknown polymorphism exists on the template DNA strand where the PCR primer anneals (43, 44) . This is unlikely to explain our results, as all our samples were previously sequenced over the whole area of primer annealing and did not reveal any further unknown polymorphisms. We have reviewed the SNP database and are unable to find any reported SNPs within the design of the primers. Although we were unable to obtain the sequence of the area spanning the forward sequencing primer binding site and possible/linked variants, we note that we have successfully used this primer for the allelic discrimination PCR, and we have never found the same samples failing with both methods. This makes it highly unlikely that there are other SNPs in that region. Although we cannot exclude the possibility of introduced errors during the process of primer synthesis, which might lead to the occurrence of null alleles as a consequence of inefficient amplification due to primer/template mismatches (43, 45) , we consider that this is unlikely.
Non-random patterns of missing genotypes introduce noise into case-control studies but can cause apparent overtransmission to affected offspring in family-based studies even if the polymorphism is not associated with the disease (46) . Our sample sizes were too small to give strong evidence that any of the genotyping platforms gave non-random patterns of missing genotypes. We note that 54.4% of the genotypes in our sample were homozygotes; yet, all four missing genotypes for the Sequenom MassARRAY Genotyping system platform were homozygotes, and all four of the missing genotypes from DNA sequencing were heterozygotes.
For case-control studies, genotype error and non-random missing genotypes can also inflate type 1 error above the nominal rate when using allelic tests that assume HardyWeinberg equilibrium (47) , such as the m 2 test or Fisher's exact test.
The distribution of SNPs at the MDR1 G2677T/A locus (rs2032582) has been reported to vary across population groups and has shown variable association with IBD. We have summarized published information on ethnic variations in unselected populations and reports on IBD patients (Table 6) . Although Schwab et al. (48) suggested that the Ser 893 variant increased susceptibility in ulcerative colitis but not Crohn's disease, Brant et al. (20) suggested that the reference genotype (G2677) increased risk, whereas other studies have failed to show an association. The allelic frequency of the A variant was reported to range from 4.4% to 21% in Asians (49, 50) compared with 0.7% to 10% in White subjects (24, 51) and 0.5% in Black subjects (52) . It is noteworthy that several different techniques have been used across different laboratories. From our data, comparisons across studies using different methodologies could be considerably misleading.
Some of the techniques that we have used, such as the Taqman SNP Genotyping Assay and RFLP, were designed on the assumption that the target was diallelic. We are aware that these assays can be re-designed to accommodate additional alleles; however, this would add to the cost of the assays and also the time involved in analyzing the samples. For RFLP, it would also depend on the presence of a suitable restriction enzyme. Clearly, when considering the type of genotyping platform to be used in a large association study, along with considering such things as the cost of genotyping, ability to multiplex, the time and handling involved, and/or access to the technology, one also needs to consider the likelihood of encountering a multiallelic SNP in the collection of SNPs being analyzed.
On the basis of the triallelic variant G2677T/A in the MDR1 gene, we have shown different detection techniques (Taqman SNP Genotyping Assay, LightCycler, allelic discrimination PCR, DNA sequencing, Sequenom MassARRAY Genotyping system, and RFLP). Our data lead us to suggest that multiallelic SNPs may be more common than generally realized, may have been overlooked in some studies, and could lead to erroneous overestimation of the frequency of certain alleles. In general, we conclude that more attention is required in the initial analysis of SNPs to determine whether they are multiallelic, perhaps by DNA sequence analysis of a reasonable number of samples. We consider that in some situations, failure to recognize the triallelic nature of the SNP may lead to the over or underestimation of real genetic associations.
